Cargando…

Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update

Myelodysplastic syndrome (MDS) is a diverse hematological malignancy with a wide spectrum of presentations and implications. Treatment strategies for patients with MDS heavily rely on prognostic scoring systems, such as the revised international prognostic scoring system (IPSS-R). Bone marrow fibros...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jain, Akriti G., Zhang, Ling, Bennett, John M., Komrokji, Rami
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for Laboratory Medicine 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677477/ https://www.ncbi.nlm.nih.gov/pubmed/34907099 http://dx.doi.org/10.3343/alm.2022.42.3.299

Ejemplares similares

Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
por: Volpe, Virginia O., et al.
Publicado: (2021)

Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes
por: Abou Zahr, Abdallah, et al.
Publicado: (2014)

Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes
por: Kouroukli, Olga, et al.
Publicado: (2022)

Bone marrow niches in myelodysplastic syndromes
por: Tosato, Giovanna, et al.
Publicado: (2021)

BMT for Myelodysplastic Syndrome: When and Where and How
por: Jain, Akriti G., et al.
Publicado: (2022)

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2021)

Responses to Sars-Cov-2 Vaccines in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Jain, Akriti G, et al.
Publicado: (2021)

Practical Guide to Bone Marrow Sampling for Suspected Myelodysplastic Syndromes
por: Ridgeway, Jean A., et al.
Publicado: (2017)

Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis
por: Ramos, Fernando, et al.
Publicado: (2016)

Early Improvement in Marrow Fibrosis Following Haploidentical Stem Cell Transplantation for a Patient with Myelodysplastic Syndrome with Bone Marrow Fibrosis
por: Takahashi, Shuichiro, et al.
Publicado: (2016)

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes
por: Garcia, Jacqueline S, et al.
Publicado: (2010)

Analysis of Immune-Cell Distribution of Bone Marrow in Patients with Myelodysplastic Syndrome
por: Lin, Chun-Liang, et al.
Publicado: (2023)

Nature or Nurture? Role of the Bone Marrow Microenvironment in the Genesis and Maintenance of Myelodysplastic Syndromes
por: Mian, Syed A., et al.
Publicado: (2021)

The implication of identifying JAK2(V617F) in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis
por: Olsen, Randall J., et al.
Publicado: (2008)

The bone marrow stroma in human myelodysplastic syndrome reveals alterations that regulate disease progression
por: Kfoury, Youmna S., et al.
Publicado: (2023)

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
por: Komrokji, R. S., et al.
Publicado: (2016)

Human bocavirus is not detectable in bone marrow from patients with myelodysplastic syndromes
por: Schildgen, Verena, et al.
Publicado: (2011)

Bone Marrow Fibrosis at Diagnosis and during the Course of Disease Is Associated with TP53 Mutations and Adverse Prognosis in Primary Myelodysplastic Syndrome
por: Zhao, Youshan, et al.
Publicado: (2022)

The growth of myelodysplastic bone marrow in long-term cultures.
por: Borbenyi, Z., et al.
Publicado: (1987)

Dysfunctional bone marrow endothelial progenitor cells are involved in patients with myelodysplastic syndromes
por: Xing, Tong, et al.
Publicado: (2022)

Immune checkpoints bone marrow expression as the predictor of clinical outcome in myelodysplastic syndrome
por: Tcvetkov, Nikolai, et al.
Publicado: (2020)

Increased Expression of Interferon Signaling Genes in the Bone Marrow Microenvironment of Myelodysplastic Syndromes
por: Kim, Miyoung, et al.
Publicado: (2015)

When Ring Sideroblasts on Bone Marrow Smears Are Inconsistent with the Diagnosis of Myelodysplastic Neoplasms
por: Girard, Sandrine, et al.
Publicado: (2022)

Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)
por: Brunner, Andrew M., et al.
Publicado: (2022)

U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes
por: Komrokji, Rami, et al.
Publicado: (2022)

Deep learning application of the discrimination of bone marrow aspiration cells in patients with myelodysplastic syndromes
por: Lee, Nuri, et al.
Publicado: (2022)

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
por: Komrokji, Rami S., et al.
Publicado: (2022)

Purification of Bone Marrow Clonal Cells from Patients with Myelodysplastic Syndrome via IGF-IR
por: He, Qi, et al.
Publicado: (2015)

Isolation, culture, and immunophenotypic analysis of bone marrow HSPCs from patients with myelodysplastic syndromes
por: Ganan-Gomez, Irene, et al.
Publicado: (2022)

Hypoplastic myelodysplastic syndrome and acquired aplastic anemia: Immune-mediated bone marrow failure syndromes (Review)
por: Votavova, Hana, et al.
Publicado: (2021)

IDH mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy
por: Komrokji, Rami, et al.
Publicado: (2022)

GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome
por: Zhou, Jing‐Dong, et al.
Publicado: (2016)

Myelodysplastic hematopoiesis mimicking the bone marrow in a mediastinal myelolipoma
por: Takano, Hina, et al.
Publicado: (2017)

Bone marrow derived stromal cells from myelodysplastic syndromes are altered but not clonally mutated in vivo
por: Jann, Johann-Christoph, et al.
Publicado: (2021)

Common and different alterations of bone marrow mesenchymal stromal cells in myelodysplastic syndrome and multiple myeloma
por: Choi, Hayoung, et al.
Publicado: (2020)

Effect of DLK1 on tumorigenesis in CD34(+)CD38(−) bone marrow cells in myelodysplastic syndromes
por: ZHANG, WEI, et al.
Publicado: (2013)

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes
por: Komrokji, Rami S., et al.
Publicado: (2023)

PB2028: ACQUIRED Α-THALASSEMIA IN A PATIENT WITH HIGH-RISK MYELODYSPLASTIC SYNDROME AND BONE MARROW FIBROSIS: CASE REPORT AND LITERATURE REVIEW
por: Chissan, Sofia, et al.
Publicado: (2023)

The spectrum of genetic mutations in myelodysplastic syndrome: Should we update prognostication?
por: Cook, Michael R., et al.
Publicado: (2021)

IRAK1 expression in bone marrow cells does not impact patient outcomes in myelodysplastic syndromes
por: de Melo Campos, Paula, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_71i0l9gvujfmac6smqsni8jv4d